Table 3.
Characteristics of asthma, COPD, and disease control having GERD
| Asthma | COPD | Disease control | |
|---|---|---|---|
| Frequency of GERD, %, GERD pt/total pt | 25.0, 10/40 | 32.5, 13/40 | 27.5, 11/40 |
| Age, year | 64.2 ± 9.8 | 72.2 ± 7.5* | 64.3 ± 7.5 |
| Sex (male/female) | 2/8 | 13/0* | 4/7 |
| Body mass index, kg/m2 | 22.8 ± 4.4 | 20.7 ± 3.6 | 22.7 ± 2.6 |
| Smoking, pack-years | 10.0 ± 31.6 | 28.9 ± 16.5* | 4.1 ± 8.3# |
| Smoking, cur-, ex-, never- | 0, 0, 10 | 4, 9, 0 | 2, 2, 8 |
| Eosinophil of peripheral blood, % | 3.4 ± 1.1 | 0.3 ± 1.1* | |
| Sputum, % | |||
| neutrophils | 59.1 ± 32.4 | 92.5 ± 5.8* | |
| eosiniphils | 33.1 ± 34.5 | 6.4 ± 5.5* | |
| metachromatic cells (basophils) | 0.29 ± 0.76 | 0 | |
| macrophages | 7.1 ± 7.4 | 1.1 ± 0.85* | |
| Pulmonary functions | |||
| %VC, % | 93.2 ± 18.5 | 67.0 ± 17.1* | |
| FVC, L | 2.1 ± 0.40 | 1.9 ± 0.66 | |
| FEV 1.0, L | 1.5 ± 0.4 | 0.93 ± 0.3* | |
| FEV 1.0% pred, % | 81.9 ± 28.1 | 52.9 ± 16.1 | |
| FEV 1.0/FVC, % | 72.2 ± 22.3 | 50.8 ± 10.1 | |
| Regular use of medication | |||
| Oral corticosteroids | 2 | 0 | |
| Oral theophyllines | 6 | 5 | |
| Oral expectrants | 2 | 2 | |
| Oral anti-histamines | 1 | 0 | |
| Leukotrienes | 4 | 0 | |
| β2 agonist patches | 8 | 3 | |
| Inhaled steroids | 2 | 6 | |
| Inhaled β2 agonists | 0 | 0 | |
| Inhaled steroids/β2 agonists | 6 | 1 | |
| Inhaled anticholinergics | 0 | 8 |
*Statistically significance between asthma patients and COPD patients. #Statistically significance between COPD patients and disease control patients.